$AHCO

AdaptHealth Corp.

No enriched coverage for $AHCO in the last 7 days.

No SEC Form 4 filings for $AHCO in the last 30 days.

See all $AHCO insider activity →
Med

Why AdaptHealth (AHCO) Stock Is Down Today

AdaptHealth (AHCO) shares fell 8.6% after announcing Harriss T. Currie as CFO, replacing Jason Clemens. The company reported a Q2 loss of $0.99 per share, missing estimates, and cut 2026 revenue guidance to $2.87B. The stock is down 41.6% YTD and 57.8% from its 52-week high.

AdaptHealth Corp. (AHCO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

AdaptHealth Corp. (AHCO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 ADAPTHEALTH CORP. FOR IMMEDIATE RELEASE AdaptHealth Appoints Harriss Currie as Chief Financial Officer PLYMOUTH MEETING, Pa. – September 8th 2026 - AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”) , a national leader in providing patient-centered, he

AHCO sentiment & insider activity

Recent AHCO coverage spans earnings, corporate actions and financial news.

What's driving AHCO

AlphAI scores every news story that mentions AHCO with an AI model for sentiment and relevance, and aggregates insider trades from AdaptHealth Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AHCO

Score

Why AdaptHealth (AHCO) Stock Is Down Today

AdaptHealth (AHCO) shares fell 8.6% after announcing Harriss T. Currie as CFO, replacing Jason Clemens. The company reported a Q2 loss of $0.99 per share, missing estimates, and cut 2026 revenue guidance to $2.87B. The stock is down 41.6% YTD and 57.8% from its 52-week high.

AdaptHealth Corp. (AHCO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

AdaptHealth Corp. (AHCO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 ADAPTHEALTH CORP. FOR IMMEDIATE RELEASE AdaptHealth Appoints Harriss Currie as Chief Financial Officer PLYMOUTH MEETING, Pa. – September 8th 2026 - AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”) , a national leader in providing patient-centered, he

$AHCOMedAI 8/10

AdaptHealth Cuts 2026 Outlook as Contract Costs Hit Margins

AdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.

$CRWVMed

Stocks Still Await Signs of Price Stability: Stock Market Today

U.S. indexes drifted lower as crude oil and interest rates were mostly flat, with investors awaiting the July CPI report. FactSet data for 88% of S&P 500 firms showed 86% positive earnings surprises and 76% positive revenue surprises. Nasdaq fell 0.6% to 26,445, S&P 500 0.3% to 7,728, Dow 0.3% to 53,791. CoreWeave (CRWV) and Super Micro (SMCI) report after the close; Nvidia (NVDA) and Intel (INTC) were also discussed.

$AHCOHighAI 9/10

AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript

AdaptHealth (AHCO) reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, with organic revenue growth of 15.9%. Adjusted EBITDA was $132 million, down 3.2%, and full-year revenue guidance was cut to $2.85-$2.89 billion with adjusted EBITDA of $490-$520 million. The company cited West Coast contract costs and a $30 million supplier price headwind, plus a $235 million diabetes divestiture.

$AHCOMed

AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth

AdaptHealth (NASDAQ:AHCO) said it will sell its diabetes unit to focus on sleep and respiratory. The deal is expected to leave about $60 million of overhead costs in continuing operations, with roughly half removed in year one. Q2 revenue grew 16%, including West Coast expansion, while the company works on contract onboarding and supplier rebate terms.

$AHCOLow

Adapthealth director Kenneth Samet buys $149,930 in shares

AdaptHealth Corp. (NASDAQ:AHCO) director Kenneth A. Samet bought 23,500 shares on Aug. 6, 2026 at $6.38 each for about $149,930. After the purchase, he beneficially owns 48,569 shares. The stock is near its 52-week low. The company recently reported a Q2 adjusted loss of $0.99 vs a $0.15 expected profit, with revenue of $740.3 million.

Related tickers